Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Key Points

• This research aims to assess the efficacy of osimertinib in patients with postoperative recurrent non-small-cell lung cancer (NSCLC) harboring EGFR mutations.
• Evaluated patients with postoperative recurrent NSCLC.
• Analyzed the effect of osimertinib treatment on disease progression.
• Postoperative recurrent disease was identified as an independent favorable prognostic factor in patients receiving osimertinib for NSCLC harboring EGFR mutations.

Abstract